Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

402 OLANZAPINE
(2006): Ozcanli T+, Prog Neuropsychopharmacol Biol Psychiatry
30(6), 1163
Hypersensitivity
(2001): Raz A+, Am J Med Sci 321(2), 156
Myalgia/Myositis/Myopathy/Myotoxicity (>1%)
(2006): Waring WS+, Hum Exp Toxicol 25(12), 735
(2001): Rosebraugh CJ+, Ann Pharmacother 35(9), 1020
Rhabdomyolysis
(2005): Baumgart U+, Pharmacopsychiatry 38(1), 36
(2001): Rosebraugh CJ+, Ann Pharmacother 35(9), 1020
(2000): Shuster J, Nursing 30(9), 87
(1999): Marcus EL+, Ann Pharmacother 33(6), 697
(1999): Wyderski RJ+, Ann Pharmacother 33(7–8), 787
(1996): Meltzer HY+, Neuropsychopharmacology 15(4), 395
OLMESARTAN
Trade name: Benicar (Sankyo)
Indications: Hypertension
Category: Angiotensin II receptor antagonist
Half-life: ~13 hours
Clinically important, potentially hazardous interactions
with: ephedra, garlic, ginseng, lithium
Reactions
Skin
Angioedema
(2007): Nykamp D+, Ann Pharmacother 41(3), 518
Facial edema
Lichen planus
(2006): Sontheimer RD, Oklahoma City, OK (from Internet)
(observation)
Lichenoid eruption
(2006): Sontheimer R (from Internet) (observation)
Peripheral edema (>0.5)
Rash (sic) (0.5%)
Other
Cough (0.7%)
Myalgia/Myositis/Myopathy/Myotoxicity (>0.5%)
Pain (>0.5%)
Upper respiratory infection (>1%)
OLOPATADINE
Trade name: Patanol (Alcon)
Indications: Pruritus due to allergic conjunctivitis
Category: Histamine H1 receptor antagonist
Half-life: 3 hours
Reactions
Skin
Burning
(2003): Ganz M+, Adv Ther 20(2), 79
Pruritus
Eyes
Eyelid burning (